Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2009
Reporting Period: The filing announces financial results for the three and six months ended June 30, 2009.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on August 6, 2009, detailing the results of operations and financial condition.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Important Facts for Investors to Verify
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the periods ended June 30, 2009.
- Verify year-over-year and quarter-over-quarter performance trends not included in this summary.
- Note the legal disclaimer regarding the "filed" status of the financial data within this specific 8-K document.
- Confirm the identity of the signatory: Thomas McNaughton, Chief Financial Officer and Principal Accounting Officer.